Sagimet Biosciences (SGMT) Liabilities and Shareholders Equity (2023 - 2024)
Historic Liabilities and Shareholders Equity for Sagimet Biosciences (SGMT) over the last 2 years, with Q3 2024 value amounting to $174.8 million.
- Sagimet Biosciences' Liabilities and Shareholders Equity rose 6980.81% to $174.8 million in Q3 2024 from the same period last year, while for Sep 2024 it was $655.0 million, marking a year-over-year change of. This contributed to the annual value of $96.7 million for FY2023, which is N/A changed from last year.
- According to the latest figures from Q3 2024, Sagimet Biosciences' Liabilities and Shareholders Equity is $174.8 million, which was up 6980.81% from $189.0 million recorded in Q2 2024.
- Sagimet Biosciences' 5-year Liabilities and Shareholders Equity high stood at $194.5 million for Q1 2024, and its period low was $21.5 million during Q2 2023.